首页> 外文期刊>European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology >Clinical application of genomic high-throughput data: Infrastructural, ethical, legal and psychosocial aspects
【24h】

Clinical application of genomic high-throughput data: Infrastructural, ethical, legal and psychosocial aspects

机译:基因组高吞吐量数据的临床应用:基础设施,道德,法律和心理社会方面

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Genomic high-throughput technologies (GHTT) such as next-generation sequencing represent a fast and cost-effective tool toward a more comprehensive understanding of the molecular background of complex diseases. However, technological advances contrast with insufficient application in clinical practice. Thus, patients, physicians, and other professionals are faced with tough challenges that forestall the efficient and effective implementation. With the increasing application of genetic testing, it is of paramount importance that physicians and other professionals in healthcare recognize the restrictions and potential of GHTT, in order to understand and interpret the complex data in the context of health and disease. At the same time, the growing volume and complexity of data is forever increasing the need for sustainable infrastructure and state-of-the-art tools for efficient data management, including their analysis and integration. The large pool of sensitive information remains difficult to interpret and fundamental questions spanning from billing to legal, social, and ethical issues have still not been resolved. Here we summarize and discuss these obstacles in an interdisciplinary context and suggest ways to overcome them. Continuous discussion with clinicians, data managers, biostatisticians, systems medicine experts, ethicists, legal scholars, and patients illuminates the strengths, weakness, and current practices in the pipeline from biomaterial to sequencing and data management. This discussion also highlights the new, cross-disciplinary working collaborations to realize the wide-ranging challenges in clinical genomics including the exceptional demands placed on the staff preparing and presenting the data, as well as the question as to how to report the data and results to patients. (C) 2019 Published by Elsevier B.V.
机译:基因组高吞吐量技术(GHTT),如下一代测序代表了一种快速且具有成本效益的工具,旨在更全面地了解复杂疾病的分子背景。然而,技术进步与临床实践中的应用不足造影。因此,患者,医师和其他专业人员面临着艰难的挑战,这些挑战是突破有效和有效的实施。随着遗传检测的应用越来越多,医疗保健中的医生和其他专业人员都认识到GHTT的限制和潜力至关重要,以便在健康和疾病的背景下理解和解释复杂数据。与此同时,数据的增长和复杂性是永远越来越需要对有效数据管理的可持续基础设施和最先进的工具,包括他们的分析和集成。大型敏感信息仍然难以解释和从计费到法律,社会的基本问题,道德问题仍未得到解决。在这里,我们总结并在跨学科的背景下讨论这些障碍,并建议克服它们的方法。与临床医生,数据管理器,生物统计学家,系统医学专家,伦理学家,法律学者和患者持续讨论,从生物材料到排序和数据管理中阐明管道中的优势,弱点和现状。该讨论还突出了新的跨学科工作合作,以实现临床基因组织中的广泛挑战,包括在员工准备和提交数据的员工,以及如何报告数据和结果的问题对患者。 (c)2019年由elestvier b.v发布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号